Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Aprea Therapeutics, Inc. (APRE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/24/2023 8-K Resignation/termination of a director
08/10/2023 8-K Quarterly results
07/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/08/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement"
02/24/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between Aprea Therapeutics, Inc. and Maxim Group LLC",
"Opinion of DLA Piper LLP (US)",
"Aprea Therapeutics Announces Proposed Public Offering of Common Stock DOYLESTOWN, Pa., February 22, 2023 Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced it has commenced an underwritten public offering of shares of its common stock. All shares of common stock in the offering are to be sold by Aprea. In addition, Aprea intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering ma...",
"Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock DOYLESTOWN, PA., February 22, 2023 Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced the pricing of its previously announced underwritten public offering of 1,050,000 shares of its common stock at a public offering price of $5.25 per share. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $5.5 million before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Aprea has granted the underwriter a 30-day option to pu..."
02/13/2023 8-K Quarterly results
02/10/2023 8-K Quarterly results
01/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aprea Therapeutics Appoints John Hamill as Chief Financial Officer DOYLESTOWN, PA, January 30, 2023 – Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced the appointment of John Hamill as Chief Financial Officer. Mr. Hamill joins Aprea with more than 30 years of finance and accounting experience. “Aprea Therapeutics has made substantial progress and is now reaching an exciting inflection point given the advancement of our ATR inhibitor in Phase 1 human clinical trials. I look forward to working closely with John to advance our mission of finding ways to revolutionize the treatment of cancer for patients in need of new therapies,” said Oren Gilad, Ph.D., Presi..."
01/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Exhibit 99.1",
"2 Understanding DDRi’s In the Clinic: Why is Toxicity Such a Big Issue? January 2023"
01/09/2023 8-K Quarterly results
11/17/2022 8-K Quarterly results
11/16/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
09/16/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/19/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
08/02/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/29/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/01/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
01/13/2022 8-K Investor presentation
Docs: "22.4 50 47 ORR 65.4 48.7 73 62"
12/09/2021 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets December 31, 2020 Assets Current assets: Cash and cash equivalents $ 61,428,404 $ 89,017,686 Prepaid expenses and other current assets 750,929 3,399,019 Total current assets 62,179,333 92,416,705 Property and equipment, net 27,318 38,515 Right of use lease and other noncurrent assets 278,209 349,999 Total assets $ 62,484,860 $ 92,805,219 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,548,388 $ 4,503,619 Accrued expenses 6,267,429 10,571,237 Lease liability—current 223,999 256,309 Total current liabilities 9,039,816 15,331,165 Lease liability—noncurrent 29,773 78,847 Total liabilities 9,069,589 15,410,012 Commitments and contingencies Stockholders’ equity: Common stock, par value $0.001; 21,360,14..."
10/15/2021 8-K Resignation/termination of a director
08/12/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy